ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in Rodents
dc.contributor.author | Cai, Shuang | |
dc.contributor.author | Xie, Yumei | |
dc.contributor.author | Davies, Neal M. | |
dc.contributor.author | Cohen, Mark S. | |
dc.contributor.author | Forrest, M. Laird | |
dc.date.accessioned | 2017-04-26T15:59:32Z | |
dc.date.available | 2017-04-26T15:59:32Z | |
dc.date.issued | 2010-06 | |
dc.identifier.citation | Cai, S., Xie, Y., Davies, N. M., Cohen, M. S., & Forrest, M. L. (2010). Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in Rodents. Journal of Pharmaceutical Sciences, 99(6), 2664–2671. http://doi.org/10.1002/jps.22016 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23783 | |
dc.description.abstract | Cisplatin (CDDP) is an effective anticancer agent for many solid tumors but has significant systemic toxicity limiting its use in many patients. We have designed a loco-regional delivery system to increase platinum levels in the lymphatics, where early metastasis is most likely to occur, while reducing systemic toxicities. CDDP was conjugated to a biocompatible polymer hyaluronan (HA), with a conjugation degree of approximately 20% (w/w). Conjugates were delivered via subcutaneous injection into the mammary fat pad of rats. Intravenous hyaluronan–cisplatin (HA–Pt) exhibited an increased plasma area under the curve (AUC) 2.7-fold compared to conventional CDDP but with a reduced peak plasma level (Cmax), and HA–Pt increased the ipsilateral lymph node AUC by 3.8-fold compared to CDDP. Urine creatinine was unchanged over 30 days following dosing of HA–Pt. This study demonstrates that intralymphatic drug delivery with polymer-conjugated platinum may provide greater tissue and systemic plasma concentrations of platinum than intravenous CDDP. In addition, localized particle delivery augmented distribution in the loco-regional tissue basin where tumor burden predominates, while renal toxicity compared to standard intravenous CDDP was significantly reduced. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 4.0 (CC BY-NC-ND 4.0), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Cancer Chemotherapy | en_US |
dc.subject | Pharmacokinetics | en_US |
dc.subject | Biodegradable polymers | en_US |
dc.subject | Controlled release | en_US |
dc.subject | Lymphatic transport | en_US |
dc.subject | Polymeric drug carrier | en_US |
dc.subject | Polymeric drug delivery systems | en_US |
dc.title | Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in Rodents | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Cai, Shuang | |
kusw.kuauthor | Xie, Yumei | |
kusw.kuauthor | Forrest, M. Laird | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.1002/jps.22016 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC3102643 | en_US |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 4.0 (CC BY-NC-ND 4.0), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.